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Brett Froeliger

Southern Illinois University–Carbondale

Southern Illinois University–Carbondale and
Duke University

Smokers may use nicotine to self-medicate for situation-specific or person-specific cognitive
or affective deficits. Although evidence suggests that nicotine replacement therapy (NRT),
relative to placebo, enhances spatial working memory (SWM) in smoking-abstinent smokers
with schizophrenia, the extent to which NRT may be helpful in attenuating abstinence-related
SWM in other groups with deficits in SWM is unknown. Depressive symptoms are associated
with both tobacco smoking and deficits in SWM. Previous studies have found that smoking
abstinence increases depressive affect and depression-related hemispheric asymmetries in
brain activation. Although the serotonin neurotransmitter system is closely associated with
depression and the effects of nicotine, the authors are not aware of any studies that have
evaluated the possible role of individual differences in serotonin transporter (5-HTT) genotype and depressive symptoms as moderators of the effects of NRT on SWM. Thus, the
current study assessed the effects of NRT (nicotine patch) on SWM in relation to: (1)
depressive traits and (2) 5-HTT genotype. Smoking-deprived habitual smokers (N ⫽ 64)
completed the dot recall test of SWM during counterbalanced and double-blind nicotine and
placebo testing sessions. There was a marginal overall effect of NRT on SWM. More
importantly, NRT enhanced SWM in 5-HTT short allele carriers, relative to those with two
long alleles, and this enhancement in short-allele carriers was greater for individuals with
higher levels of depressive symptoms.
Keywords: nicotine, depression, serotonin, genetics, spatial processing

There is a high prevalence of smoking in individuals with
a mental health history; particularly schizophrenia and depression (Kirch, 2000). Smokers with more depressive episodes tend to have greater nicotine dependence (Breslau,
Kilbey, & Andreski, 1991), greater tendency to relapse
when trying to quit smoking (Glassman et al., 1988), and
more depressive episodes when trying to quit smoking
(Covey, Glassman, & Stetner, 1997). Additionally, it appears that in neurodegenerative disorders such as Parkin-

son’s and Alzheimer’s diseases there is a neuroprotective
effect of nicotine where individuals who smoke are less
likely to exhibit the symptoms of these diseases (Newhouse
& Whitehouse, 2000). Although the causal nature of the
relationship between nicotine usage and mental health is
unclear, it has been hypothesized that individuals use nicotine to self-medicate for various mental deficits (Carmody,
1989; Hughes, Hatsukami, Mitchell, & Dahlgren, 1986; Newhouse, Potter, & Singh, 2004; Newhouse, Singh, & Potter,
2004). At a nonclinical level, individuals with high levels of
neurotic, depressive, and anxious personality traits may use
nicotine to alleviate negative mood symptoms associated with
these negative affect related traits (Eysenck, 1980; Gilbert,
Sharpe, Ramanaiah, Detwiler, & Anderson, 2000).
Consistent with the self-medication model, research has
demonstrated that smokers with schizophrenia, relative to
matched control smokers, show impairments in spatial
working memory (SWM) during nicotine abstinence
(George et al., 2002) and this impairment is alleviated upon
resumption of nicotine usage (Sacco et al., 2005). Although
NRT appears to reduce abstinence-related impairments of
spatial processing in schizophrenia (George et al., 2002;
Sacco et al., 2005), it is unclear as to what extent nicotine
enhances (or nicotine deprivation in habitual smokers impairs) spatial processing in other individuals or populations
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with spatial processing deficits. Individuals with depressive
traits, including those with major depressive disorder, have
been found to exhibit SWM deficits (Henriques & Davidson, 1997; Miller, Fujioka, Chapman, & Chapman, 1995).
Depression has been hypothesized to be associated with a
general perceptual deficit in posterior right hemisphere
(RH) processing (Heller, Etienne, & Miller, 1995). The
spatial processing deficits of those high in depressive traits
have been shown to be associated with decreased posterior
RH activity (Henriques & Davidson, 1997; Miller et al.,
1995; Rabe, Debener, Brocke, & Beauducel, 2005). In addition to these posterior brain asymmetries, depression is
associated with frontal brain asymmetries (decreased LH
relative to RH frontal cortical processing; Davidson, 1992;
Davidson, Pizzagalli, Nitschke, & Putnam, 2002). Research
indicates that negative affect-related frontal asymmetries
are modulated by nicotine (Gilbert, Robinson, Chamberlin,
& Spielberger, 1989) and that NRT decreases negative
affect in smoking abstinent smokers (Gilbert, Rabinovich et
al., 2008). The extent to which nicotine may improve depression related spatial processing is unknown, though a
recent study (Gilbert, Carlson, Riise, Rabinovich, Sugai, &
Froeliger, 2008) found that, in abstinent smokers, NRT
enhanced LH processing and decreased RH processing of
affective word stimuli and that NRTs effects on RH affective word processing were moderated by depressive traits.
Nonetheless, while nicotine modulates affect-related information processing asymmetries (Gilbert et al., 1989), its
influence on SWM is untested.
The serotonin transporter (5-HTT)-linked polymorphic
region (5-HTTLPR) is a functional polymorphism in the
promoter for the serotonin transporter gene that encodes a
short (S) and a long (L) allele type. The homozygous L
genotype (compared to S allele carriers) is associated with
greater 5-HT reuptake and presumably lower levels of synaptic 5-HT (Hariri et al., 2002; Heinz et al., 2000; Lesch et
al., 1996; Little et al., 1998). The S allele appears to be
associated with increased emotional reactivity to life stressors (Hariri & Holmes, 2006; Joober, Sengupta, & Schmitz,
2007) and to interact with stressful life events in predicting
depressive symptoms, clinical depression, and number of
suicide attempts (Caspi et al., 2003). Nicotine enhances the
release of serotonin, which may play a role in nicotine
dependence (Ribeiro, Bettiker, Bogdanov, & Wurtman,
1993). Smoking-related behavior, including smoking to reduce negative mood, appears to be associated with interactions of 5-HTTLPR genotype and neuroticism (Hu et al.,
2000; Lerman et al., 2000; but see Munafò, Roberts, Johnstone, Walton, & Yudkin, 2005 for alternative results).
Additionally, individuals with the S allele of the 5-HTT
gene have been shown to experience greater negative affect
related tobacco abstinence symptoms (Gilbert, Zuo, et al., in
press), which is consistent with previous associations of
serotonergic hypofunctioning with nicotine abstinence in
animal models (Harrison, Liem, & Markou, 2001) and with
negative affect in human samples (Lesch & Merschdorf,
2000).
In summary, nicotine, 5-HTT genotype, and depression
are associated with each other and S allele carriers have

been found to experience greater severity of smoking abstinence symptoms (Gilbert et al., in press). Hariri and Holmes
(2006) concluded that the S allele increases emotional reactivity to stressors. Given that most smokers experience
smoking abstinence as a stressor, one might expect the S
allele to be associated with heightened reactivity to nicotine
abstinence. However, we are not aware of any study that has
assessed whether nicotine replacement therapy (NRT) is
effective in enhancing SWM in nicotine-deprived S allele
carrying habitual smokers.
Therefore, the aim of the current study was to assess the
roles of depressive symptoms and 5-HTT genotype on the
putative benefits of NRT on SWM in overnight-deprived
nicotine-dependent smokers. It was hypothesized that NRT
in general would enhance SWM, that theses effects would
be stronger in individuals with higher levels of depressive
symptoms or in 5-HTT short allele carriers, and strongest in
individuals who are both 5-HTT short allele carriers and
have high levels of depressive symptoms.

Method
Participants
Thirty-one female and 33 male smokers (N ⫽ 64) between the ages of 18 to 50 (M ⫽ 26, SD ⫽ 8.80) who
smoked an average of ⱖ10 (M ⫽ 17, SD ⫽ 5.74) cigarettes
per day for the past year, and had a mean Fagerström Test
of Nicotine Dependence (FTND; Heatherton, Kozlowski,
Frecker, & Fagerström, 1991) score of 4.00 (SD ⫽ 1.91)
participated in the study. There were 5 African American, 3
multiracial, and 56 White participants in the sample.
Participants were recruited by newspaper ads and postings
throughout a Midwestern university campus and surrounding
community. Exclusion criteria included smoking fewer than 10
cigarettes per day for the past year, smoking cigarettes with
Federal Trade Commission (FTC) nicotine deliveries of less
than 0.6 mg/cigarette, reported use of psychoactive drugs or
medications other than caffeine, marijuana, and alcohol, excessive alcohol use (30⫹ drinks/week), ages less than 18 or
more than 50, non-English speaking, atypical sleep cycles, and
serious medical, hearing, and visual problems. Participants
were instructed not to smoke tobacco or drink alcohol for
the 12 hours preceding each of the experimental sessions and
not to smoke marijuana for at least 72 hours before the sessions. Only those who reported adhering to these requirements
and who had breath CO concentrations of less than 10 ppm
were included in data analyses.

Orientation Sessions
During an orientation session participants provided
breath CO samples to verify habitual smoking (M ⫽ 21.03,
SD ⫽ 9.00) and completed the Minnesota Multiple Personality Inventory-2 (Hathaway & McKinley, 1983) depression
scale and the Fagerström Test of Nicotine Dependence
(Heatherton et al., 1991).
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Questionnaires

placebo patch. Before each experimental day, participants
were instructed to abstain from smoking for 12 hours preceding the experimental session.
Assessment of smoking abstinence. Compliance with
instructions for overnight smoking abstinence and smoking
status were monitored using self-report and expired breath
CO concentrations assessed with a MiniCO7 m (Catalyst
Research Corporation, Owings Mills, MD). CO concentration had to be less than 10 ppm at the time of patch
placement and to be less than or equal to that when returning to the lab 4 hours later to begin the experimental session.
Mean CO values of 5.23 (SD ⫽ 3.04) and 5.20 (SD ⫽ 3.01)
at the beginning of experimental sessions one and two,
respectively, indicate participant compliance of smoking
abstinence.
Patch administration. Patch administration was doubleblind and counterbalanced for order. A researcher not involved in data collection or otherwise interacting with participants provided the appropriate nicotine or placebo patch
and kept a record of which patch was given. The nicotine
patch was a 14 mg Nicoderm transdermal patch; the placebo
patch was an identical appearing patch provided by GlaxoSmithKline. To minimize the ability of participants to differentiate active and placebo patches by skin sensations
(itching or irritation) we used a cover bandage with capsaicin cream. Both the active and placebo patches were placed
in the center of a 6.5 cm ⫻ 7.0 cm cover bandage. Then a
small amount (.05 ml) of capsaicin .075% cream (CapzasinHP7, Chattem, Inc.) was applied to the Teflon-coated surface of the cover bandage, covering an area 5 mm wide
immediately next to each of the edges of the bandage. Pilot
testing demonstrated that this procedure reduced the ability
of participants to detect differences between the active and
placebo patch when applied. The patches were placed on the
upper arm of smokers approximately 4 hours before the
beginning of the experimental sessions.
SWM task. The dot recall SWM task implemented in
the present experiment was modeled after the procedures
used by George et al. (2002). This measure has been found
to have adequate test–retest reliability and to be valid measure of SWM (Bollini, Arnold, & Keefe, 2000). Participants
performed this task during both the nicotine and placebo
patch experimental sessions. The task was displayed by a
PC on an 18-inch LCD monitor using SuperLab 2.0 soft-

FTND. The FTND (Heatherton et al., 1991) is designed
to assess nicotine dependence and is moderately predictive
of severity of withdrawal distress and relapse to smoking
(Piasecki et al., 2000).
Minnesota Multiple Personality Inventory-2. The Minnesota Multiple Personality Inventory-2 (MMPI-2) consists
of empirically derived questionnaires designed to delineate
clinical from nonclinical disorders. Here we used the MMPI
depression scale as a measure of depressive affect and
symptoms frequently associated with depression (Bence,
Sabourin, Luty, & Thackrey, 2006; Wetzler; Kahn, Strauman, & Dubro, 1989). Within healthy populations the
MMPI depression scale has been found to predict depressive symptoms (Gilbert et al., 2002) and asymmetrical neural responses (Gilbert et al., 2004) to smoking abstinence.
The mean MMPI depression scale score for men (M ⫽
18.15, SD ⫽ 4.35) and women (M ⫽ 21.84, SD ⫽ 5.65)
corresponded to T scores of 49.63 and 53.42, respectively,
which did not significantly differ from each other, p ⬎ .10.
T scores ranged from 29.60 to 68.84.

5-HT Transporter Genotyping
DNA was isolated from blood samples according to standard techniques. The 5-HTTLPR polymorphism of the
5-HTT was assessed by polymerase chain reaction (PCR)
based on the conditions described by Yonan, Palmer, and
Gilliam (2006). Specific primers and reaction conditions are
available upon request. In our sample, there were 21 LL, 29
SL, and 14 SS individuals. These proportions corresponded
to the Hardy-Weinberg distribution, 2(64) ⫽ 0.44, p ⫽ .51.
For statistical purposes, 5HTT gene is categorized as either
S allele carriers (N ⫽ 43; one or two short [S] variants
with 14 copies of a 20 to 23 base pair [bp] repeat unit, 430
bp) or homozygous LL (N ⫽ 21; two long variants consisting of 16 copies, 474 bp). As presented in Table 1, there
were no significant difference between S allele carriers and
LL individuals on a number of participant characteristics.

Experimental Procedures
Participants completed two counterbalanced experimental sessions: one with nicotine patch and the other with

Table 1
Participant Characteristics for Each 5-HTT Genotype
Frequencies
5-HTT
genotype

N

Gender

S Carrier

43

21 Male
22 Female

LL

21

12 Male
9 Female

Means and SDs
Ethnicity

39
2
2
17
3
1

White
African American
Multiracial
White
African American
Multiracial

Number of
cigarettes a day

Nicotine
dependence (FTND)

Age

Depression
(MMPID T Score)

16.88
(6.10)

3.93
(1.78)

24.86
(7.79)

50.74
(10.02)

17.43
(5.06)

4.14
(2.20)

28.57
(10.33)

52.95
(11.58)

Note. Differences between means are not significant, all ps ⬎ .10.
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Figure 1. The Dot Recall task of spatial working memory (George et al., 2002) begins with a target
dot presented at one of 16 predetermined locations. Participants then perform six tic-tack-toe
distracter tasks. After this period of distraction, participants are required to recall the exact spatial
location of the target dot with a computer mouse.

ware (Cedrus, Phoenix, AZ). The SWM task consisted of 13
trials, each with three sections. As depicted in Figure 1, the
initial section consisted of a dot presented on the computer
screen at one of 16 different predetermined locations
for 3,000 ms. The second section consisted of six different
distracter tic-tack-toe tasks, which cumulatively lasted
for 30 seconds. Participants were required to indicate
whether the tick-tack-toe game was an “X win, O win, or a
draw.” The final section required participants to indicate the
location of the initial dot by moving and clicking the computer mouse over the initial dot location.

Symptoms (as measured with the MMPI Depression scale
T scores) included as a continuous covariate.1 Given that
Depressive Symptoms was a variable of theoretical interest, the modal tested for all main and interaction
effects including this continuous variable. Where appropriate, follow-up Pearson correlations were used to better
understand interactions with Depressive Symptoms. For
demonstration purposes, participants were dichotomized
into having “high” or “low” levels of depression; overall
performance for each level of Depression, 5-HTT Genotype and Nicotine are presented in Table 2.

Results

Statistical Analyses
The primary dependent measure of interest was the
Difference in Nicotine Replacement Therapy (NRT) on
participants’ average distance from the target dot. This
measure was used to assist in interpreting associations
between differences in nicotine and placebo sessions and
MMPI-2 Depression. The Difference in NRT was defined
as the difference between a participant’s performance
with placebo patch and performance with nicotine patch
(placebo distance from target in cm—nicotine distance
from target in cm). Positive values indicated greater
performance during nicotine relative to placebo sessions,
while negative values indicated better performance during placebo relative to nicotine sessions. An analysis of
covariance (ANCOVA) with between-subjects variables
5-HTT Genotype (short allele carriers vs. long-long type)
and Gender (male vs. female) was run, with Depressive

A one-sample t test was run on the Difference in NRT to
assess whether there was an overall effect of NRT, relative
to placebo patch, on SWM. The results suggest that, in
general, nicotine marginally enhanced performance on
SWM, M ⫽ .14, SE ⫽ .08, t(63) ⫽ 1.80, p ⫽ .08.
The results of the 5-HTT Genotype, Gender, and Depressive Symptoms ANCOVA revealed two important effects of
5-HTT Genotype on the Difference in NRT. First, there was
a significant effect of 5-HTT Genotype, F(1, 56) ⫽ 5.51,
1

Although our primary focus for this article was on the 5-HTT
genotype and depressive symptoms, we did collect data for the
DRD2 genotype and ran an additional analysis with DRD2. No
significant associations were found with DRD2 on the dot recall
task. This DRD2 analysis can be obtained from the corresponding
author upon request.

SEROTONIN, DEPRESSION, NICOTINE, AND SPATIAL MEMORY

Table 2
Mean Distance (cm) From the Target Dot by Condition
High depression
Nicotine
Placebo

Low depression

LL

S Carrier

LL

S Carrier

1.64
1.47

1.00
1.41

0.85
0.92

0.94
1.00

p ⬍ .05, 2p ⫽ .09 (Figure 2a), where short allele carriers
(M ⫽ .38 cm, SE ⫽ .10) performed better with NRT on the
dot recall task of SWM, whereas long-long (LL) individuals
did not (M ⫽ –.04 cm, SE ⫽ .13). Second, there was a
significant interaction of 5-HTT Genotype with Depressive
Symptoms on the Difference in NRT on SWM, F(1,
56) ⫽ 8.22, p ⬍ .01, 2p ⫽ .13. As graphically depicted in
Figure 2, follow-up Pearson correlations revealed that for
LL individuals there was a nonsignificant negative correlation between Depressive Symptoms and the Difference in
NRT on SWM, r ⫽ ⫺.20, p ⬎ .05 (Figure 2b), whereas for
short allele carriers there was a positive correlation between
Depressive Symptoms and the Difference in NRT on SWM,
r ⫽ .38, p ⬍ .05 (Figure 2c). As presented in Table 2,
participants with high levels of depression generally performed poorly during the placebo session, but S carriers
appeared to benefit from NRT, whereas LL individuals did
not. There were no effects of gender, F(1, 56) ⫽ 1.11, p ⫽
.27, 2p ⫽ .02, or Depressive Symptoms, F(1, 56) ⫽ 1.70,
p ⫽ .20, 2p ⫽ .03, nor were there any additional interaction
effects (all ps ⬎ .10). The 5-HTT Genotype, F(1,
48) ⫽ 4.57, p ⫽ .05, 2p ⫽ .09, and the 5-HTT by Depressive Symptoms, F(1, 48) ⫽ 6.93, p ⫽ .01, 2p ⫽ .13, effects
both remained significant in a separate analysis of only
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White participants indicating that these effects were not
mediated by ethnicity differences between the short allele
carrier and LL groups.

Discussion
The finding that smoking-deprived 5-HTT S carriers,
especially those high in depressive symptoms, performed
better on a SWM task with NRT, whereas homozygous L
individuals did not, is potentially quite important. These
findings extend previous associations between 5-HTT genotype, depressive symptoms (Caspi et al., 2003; Joober et
al., 2007), affect-related brain activity (Furmark et al., 2004;
Hariri & Holmes, 2006; Hariri et al., 2002), and smoking
behavior (Hu et al., 2000; Lerman et al., 2000). The present
results suggest that 5-HTT genotype plays an important role
in moderating the cognitive benefits of NRT after a period
of nicotine deprivation; or alternatively, who experiences
the most significant SWM deterioration during nicotine
abstinence.
Although NRT on average marginally improved SWM,
closer examination revealed that S allele carriers benefited
from NRT and LL individuals did not. This suggests that the
effects of NRT on SWM are individual specific and not
universal. This notion is further supported by the positive
correlation between depressive symptoms and the difference in NRT in 5-HTT short carriers (Figure 2c). Therefore,
the results add support to trait based models of nicotine
usage and suggest that multiple genetically and environmentally influenced traits moderate an individual’s specific
response to nicotine (Eysenck, 1980; Gilbert, 1995; Lerman
et al., 2000). These results add to a growing body of
literature suggesting the 5-HTT is intimately associated
with depressive and negative affect-related symptoms

Figure 2. The 5-HTT genotype resulted in several effects of the Difference in NRT (calculated as
the placebo distance from target in cm—nicotine distance from target in centimeters) on the SWM
task. (a) Short allele carriers benefited more from NRT on SWM than homozygous LL. (b) For LL
individuals there was a nonsignificant negative correlation between Depressive Symptoms (MMPI
depression T scores) and the Difference in NRT (r ⫽ ⫺.20, p ⬎ .05). (c) On the other hand, for short
allele carriers there was a positive correlation between Depressive symptoms and the Difference in
NRT (r ⫽ .38, p ⬍ .05).
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(Caspi et al., 2003; Hariri & Holmes, 2006; Joober et al.,
2007), in addition to smoking behaviors in smokers with
high levels of neuroticism (Hu et al., 2000; Lerman et al.,
2000). Although most smokers experience smoking abstinence as a stressor, 5-HTT S carriers in particular experience greater negative affect-related symptoms during nicotine abstinence (Gilbert, Zuo, et al., in press). Thus, our
finding that 5-HTT S carriers, especially those high in
depressive symptoms, benefit from NRT (after nicotine
abstinence) on SWM is consistent with the hypothesis that
S allele carriers are generally more responsive to stressors
(Hariri & Holmes, 2006). It is not clear whether these
effects of NRT simply reflect greater abstinence-related
decrements in SWM in these populations or may reflect, at
least in part, genuine benefits that are independent of nicotine withdrawal results from smoking abstinence.
Neuroimaging studies indicate that the amygdala is more
sensitive to emotionally charged stimuli in S allele carriers,
compared to LL individuals (Furmark et al., 2004; Hariri &
Holmes, 2006; Hariri et al., 2002). The amygdala and hippocampus are involved in regulating the hypothalamicpituitary-adrenal (HPA) axis response to stress (Campbell &
Macqueen, 2004). Depression may be associated with a
dysregulated HPA response, which could contribute to depressive symptoms and hippocampal volume loss (Sheline,
Mittler, & Mintun, 2002). Hippocampal volumes are
smaller in untreated depressed individuals (Hickie et al.,
2005; MacMaster & Kusumakar, 2004; Sheline, Gado, &
Kraemer, 2003) and are correlated with deficits in visual
memory (Hickie et al., 2005). In a virtual reality task of
spatial memory, sensitive to hippocampal damage, clinically depressed individuals displayed impaired performances relative to controls (Gould et al., 2007). Animal
models implicate the hippocampus as an important mechanism in spatial memory and site of nicotine action on the
5-HT system (Kenny, File, & Rattray, 2001), which may
underlie nicotine’s antidepressant effects (Balfour & Ridley, 2000). Interestingly, other psychiatric populations associated with nicotine usage, such as those with Alzheimer’s and schizophrenia, are also associated with reduced
hippocampal volumes. Thus, this hippocampal system appears to be a likely substrate in which nicotine influences
SWM in depressed individuals with dysfunctional 5-HT
systems.
Our findings are consistent with the self-medication
model of nicotine addiction (Carmody, 1989; Eysenck,
1980; Gilbert et al., 2000; Hughes et al., 1986; Newhouse,
Potter, & Singh, 2004; Newhouse, Singh, & Potter, 2004),
which posits that smokers use nicotine to compensate for
situation- or person-specific deficits. Specifically, the results
suggest that 5-HTT S allele carriers, especially those with
high levels of depressive symptoms, may self medicate to
reduce impairments in SWM. Similar SWM impairments
have been observed in smokers with schizophrenia (George
et al., 2002) and smoking alleviates this deficit (Sacco et al.,
2005). Nicotine abstinence-related deficits in SWM and
other cognitive abilities may lead individuals to perform
uncharacteristically below their usual (self-expected) level
of performance and therefore may result in enhanced neg-

ative affect (Gilbert, 1995). Therefore, depression-prone
5-HTT S allele carriers who in general do not respond well
to stressful situations (Caspi et al., 2003) and experience
greater negative affect during nicotine abstinence (Gilbert et
al., in press) may be especially susceptible to self-medicate
with nicotine to alleviate both cognitive/SWM deficits, but
also the associated stress and frustration. Given that, 5-HTT
S carriers high in neuroticism are typically unsuccessful in
attempts to quit smoking (Hu et al., 2000), these individuals
may benefit more from NRT or additional individualized
interventions which attempt to compensate for these deficits. In particular, 5-HTT S carriers with high levels of
depression, anxiety, or neuroticism may be responsive to
antidepressant pharmacological treatments, which are effective in treating negative affect-related mood disorders
(Tamminga et al., 2002) and nicotine addiction (Cinciripini
et al., 1995). However, further research is needed to assess
the validity of these clinical hypotheses.
Given that this is the first study to assess the combined
effects of NRT, depression, and 5-HTT genotype on SWM
the clinical implications of the results should be interpreted
with caution. It remains unclear if the beneficial effects of
NRT generalize to 5-HTT S carriers with clinical levels of
depression and if highly depressed S carriers maintain nicotine usage as a form of self-medication. In addition, as
noted above, it is not clear whether the exaggerated SWM
deficits observed in the placebo, relative to the nicotine
patch condition, simply reflect more severe withdrawal
symptoms in those with low cognitive reserves. Future
research should be directed at addressing these issues.
Given that nicotine has been shown to enhance attention
(Gilbert et al., 2004), the enhancement of SWM during NRT
in 5-HTT S carriers may be a byproduct of NRT-related
enhancements in attention or general cognitive processing.
Additionally, it could be argued that individuals with high
depressive symptoms are less engaged in the task and that
NRT simply enhances motivation in these individuals. Although this explanation may be merited, it appears this
could only be the case in 5HTT S carriers as there was no
main effect of depressive symptoms. Future research using
multiple (distinct) cognitive measures should be aimed at
addressing the specifity of this NRT-related cognitive enhancement in 5-HTT S carriers (especially those high in
depressive symptoms). Finally, while gender did not moderate the effects of NRT on SWM, menstrual cycle phase
and oral contraceptive use were not assessed and could
influence the effects. A recent meta-analysis of the effects of
gender on response to NRT-related smoking cessation (Perkins & Scott, 2008) suggests that large sample sizes are
needed to reliably demonstrate gender effects on NRT.
Therefore, studies with larger samples are needed to determine the potential role of gender on the effects of NRT on
SWM.
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